Literature DB >> 9655536

Erythromycin resistance of Streptococcus pyogenes in Madrid.

B Orden1, E Perez-Trallero, M Montes, R Martínez.   

Abstract

BACKGROUND: Erythromycin is considered to be an adequate alternative to penicillin for patients who are allergic to penicillin. Erythromycin-resistant Streptococcus pyogenes strains have been reported in some parts of the world.
METHOD: The in vitro activity of erythromycin and other antimicrobial agents was determined in a total of 1310 clinical Streptococcus pyogenes isolates collected in the city of Madrid from January, 1993, through December, 1996.
RESULTS: All strains showed susceptibility to penicillin, rifampin, vancomycin and chloramphenicol. Tetracycline resistance was 8.5%. In 36 of the strains (2.7%) MIC was 4 microg/ml for ofloxacin. Clindamycin resistance was observed in only 18 strains (1.4%); this resistance was constitutive in 15 and inducible in 3 strains. Resistance to erythromycin was observed in 14.3% of the strains, showing an increase during the study period (2.0% in 1993 vs. 22.4% in 1996; chi square for linear trend 68.8, P < 0,0001); >90% of them showed the novel resistance phenotype described by Seppälä et al. and 32 of 32 of these strains showed by PCR the 1.4-kb fragment of the mefA gene recently described as the novel macrolide efflux resistance determinant. The erythromycin-resistant strains were isolated more often in pediatric patients (144 of 872) than in adults (44 of 438) (chi square 9.9, P = 0.0016).
CONCLUSION: The study emphasizes the need to screen for resistance to macrolides in S. pyogenes and indicates that resistance to erythromycin in S. pyogenes has increased significantly in Madrid.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655536     DOI: 10.1097/00006454-199806000-00006

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  11 in total

1.  Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries.

Authors:  Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 2.  Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E).

Authors:  Corné H W Klaassen; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens.

Authors:  F Baquero; J A García-Rodríguez; J García de Lomas; L Aguilar
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

4.  Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens.

Authors:  F Baquero; J A García-Rodríguez; J G de Lomas; L Aguilar
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  Phenotypic and genotypic characterization of Streptococcus pyogenes isolates displaying the MLSB phenotype of macrolide resistance in Spain, 1999 to 2005.

Authors:  Emilio Pérez-Trallero; Milagrosa Montes; Beatriz Orden; Esther Tamayo; José M García-Arenzana; José M Marimón
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

6.  Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.

Authors:  K Nagai; T A Davies; L M Ednie; A Bryskier; E Palavecino; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 7.  Clonal differences among erythromycin-resistant Streptococcus pyogenes in Spain.

Authors:  E Perez-Trallero; J M Marimón; M Montes; B Orden; M de Pablos
Journal:  Emerg Infect Dis       Date:  1999 Mar-Apr       Impact factor: 6.883

8.  Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain.

Authors:  C García-Rey; L Aguilar; F Baquero; J Casal; J E Martín
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

9.  Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia.

Authors:  Roman S Kozlov; Tatiana M Bogdanovitch; Peter C Appelbaum; Lois Ednie; Leonid S Stratchounski; Michael R Jacobs; Bülent Bozdogan
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  Erythromycin resistance in Streptococcus pyogenes in Italy.

Authors:  M Bassetti; G Manno; A Collidà; A Ferrando; G Gatti; E Ugolotti; M Cruciani; D Bassetti
Journal:  Emerg Infect Dis       Date:  2000 Mar-Apr       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.